WHO Raises Ethical Concerns Over Planned Hepatitis B Vaccine Trial in Guinea-Bissau

Understanding the Hepatitis B Threat

Hepatitis B is a viral infection that attacks the liver. It can cause both acute and chronic disease. The World Health Organization (WHO) estimates that roughly 296 million people were living with chronic hepatitis B infection in 2019. Each year, about 820,000 people die from complications like cirrhosis and liver cancer.

For newborns, the danger is especially high. If a baby catches hepatitis B during childbirth, there is a 90 percent chance they will develop a chronic, lifelong infection. This chronic infection silently damages the liver over decades. Many people do not know they are infected until serious liver damage has already occurred. The hepatitis B birth dose vaccine is the single most effective way to break this cycle of transmission.

How This Affects Readers

If you are a parent, expecting a child, or planning a family, this story matters to you. The hepatitis B birth dose is a standard of care in over 115 countries. It is given within 24 hours of birth, often right in the delivery room. When you hear about a trial that withholds this vaccine from some newborns, it raises a fundamental question: Could my child be put at risk in the name of research?

For families in Guinea-Bissau, this is not a hypothetical question. It is a real and immediate concern. The proposed trial would have given some babies the proven vaccine while others received nothing. This creates a situation where some newborns are left unprotected against a disease that can permanently harm them. The WHO’s strong statement against this trial is meant to protect not just the babies in Guinea-Bissau, but also to set a global standard that prevents similar ethical lapses elsewhere.

Why Experts Are Speaking Out

Medical ethicists and public health experts have raised alarm about this proposed trial for several reasons. Dr. Thomas Frieden, former director of the U.S. Centers for Disease Control and Prevention, has long argued that withholding proven vaccines in clinical trials is almost never justified. He and other experts point to a core principle of research ethics: the “duty of care.”

This duty means that researchers must always put the well-being of participants first. When a safe and effective vaccine already exists, giving some participants a placebo or no treatment can be seen as a violation of this duty. Experts also note that the study’s design appears to be scientifically weak. A single-blind, no-treatment control study is likely to produce biased results. This means the data collected would not be reliable enough to guide health policy anywhere in the world.

Dr. Peter Doshi, a professor of pharmaceutical health services research at the University of Maryland, has written extensively about the ethics of placebo-controlled trials. He argues that such designs are only acceptable when there is genuine uncertainty about which treatment is better. In the case of the hepatitis B birth dose, there is no uncertainty. The vaccine works. It is safe. It has been used for more than 30 years.

The Problem of Exploiting Limited Resources

One of the most troubling aspects of this case is the potential for exploitation. Guinea-Bissau is one of the poorest countries in the world. It has limited healthcare infrastructure and struggles to provide basic vaccines to all newborns. The WHO specifically states that lack of resources cannot be used as a reason to deny proven care in a research study.

Ethical guidelines, including the Declaration of Helsinki and the Council for International Organizations of Medical Sciences (CIOMS) guidelines, are clear. Research in low-resource settings must not take advantage of vulnerable populations. Participants must receive at least the same level of care they would have access to outside the study. In this case, the study appears to offer less protection than the standard of care that should be available to all newborns.

Practical Takeaways for Readers

This situation offers several important lessons for anyone interested in vaccine safety, research ethics, or global health.

What Parents Should Know

• The hepatitis B birth dose is safe and essential. It has been used for decades and prevents up to 95 percent of mother-to-child transmissions. Your baby should receive it within 24 hours of birth.
• Ask your healthcare provider. If you are pregnant, ask your doctor about hepatitis B testing and the birth dose vaccine. Knowing your status can protect your baby.
• Understand your rights. In any medical research study, you have the right to know what treatments are being withheld and why. You can always refuse to participate.

What the Public Should Watch For

• Ethical oversight matters. Clinical trials must be approved by independent ethics committees. These committees include doctors, scientists, and community members who review the study for safety and fairness.
• Transparency is key. When a study’s design is not publicly available or clearly explained, it is a red flag. Researchers should be open about their methods and their reasons for using a control group.
• Global health is connected. What happens in Guinea-Bissau affects trust in vaccines everywhere. When ethical standards are violated in one country, it can fuel vaccine hesitancy around the world.

What Happens Next in Guinea-Bissau

The WHO has offered to help Guinea-Bissau move forward in a more ethical way. Instead of a trial that withholds the vaccine, the WHO recommends focusing on practical steps to increase vaccination coverage. These steps include giving the birth dose within 24 hours for both home and hospital births, testing pregnant women for hepatitis B, and improving the cold-chain system that keeps vaccines cold during transport.

Guinea-Bissau has paused the study while further technical reviews take place. This is a positive step. It gives the country a chance to reconsider the trial’s design and to align with international ethical standards. The WHO is ready to provide technical support and to help the country introduce the birth dose vaccine as a routine part of newborn care.

A Broader Lesson for Medical Research

This case is a reminder that medical research must always balance the pursuit of knowledge with the protection of human subjects. The most vulnerable participants—newborn babies—deserve the highest level of protection. When a proven, lifesaving intervention exists, it is almost never ethical to withhold it just to answer a secondary question about safety or side effects.

The WHO’s position is clear: research must follow the highest ethical and scientific standards. Any study that fails to meet these standards should not move forward. By speaking out, the WHO is sending a message to researchers and governments around the world that ethical shortcuts are not acceptable, no matter where the research takes place.

Final Thoughts

The hepatitis B vaccine is one of the great success stories of modern medicine. It has saved millions of lives and prevented countless cases of liver cancer. Ensuring that every newborn, everywhere, has access to this vaccine is a global health priority. The proposed trial in Guinea-Bissau threatened to undermine that priority by putting some babies at risk for no good scientific reason.

Thanks to the WHO’s intervention, the trial has been paused. This gives Guinea-Bissau an opportunity to pursue a better path—one that prioritizes vaccination over experimentation. For readers, this story is a reminder that ethical standards in medical research are not optional. They are the foundation of trust between science and the public. When that trust is broken, it hurts everyone. When it is upheld, it protects the most vulnerable among us.